EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Bioventus Inc (BVS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Bioventus Inc $7.40, price $13.61, upside -45.6%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US09075A1088

BI Bioventus Inc logo Some data Sep 23, 2026

Bioventus Inc

BVS · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $7.40 · Strongly overvalued (−46%)
!Quality 58/100
!Mixed Growth (revenue 5y +12.1 %/yr)
!Thin margins · 4.9% net margin (TTM)
!High debt · generates free cash flow
✓Ranks above peers (9/14)
!Moderate moat 47/100
!Insider activity 46/100
!Evidence only medium, so the estimate is less certain
!Weak on balance sheet: 24 out of 100
Watch Bioventus Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.80 $0.9261 Fair Value $7.40 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.9261 – $18.80 · fair‑value band $5.54 – $10.77 · the $13.61 price screens above the $7.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Bioventus in your weekly email

Every Wednesday you see whether Bioventus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.

Show more

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Stock analysis

Bioventus Inc (BVS) currently trades at $13.61, while our model-based Fair Value estimate is $7.40, implying the stock looks roughly 83.9% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $12.26 per share, and 6 of the 24 models we run sit above the $13.61 price.

Bear case: the Asset-Based group reads lowest at $1.82, and 18 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $5.54 (bear) to $10.77 (bull), the price of $13.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bioventus Inc reported revenue of $568M in FY2025 versus $431M in FY2021, a compound +7.2%/yr. Reported net income was $22.7M in FY2025, compounding +4.1%/yr from FY2021.

Key figures

Market cap $938M · P/E ratio 33.2 · P/S ratio 1.33 · EPS (TTM) $0.4100 · Net margin 4.0% · Return on equity 16.5% · Return on assets (EBIT) −2.9% · Operating margin 6.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 11% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −46%, BVS screens richer than that median.

Fair Value models

Bear $5.54 Fair Value $7.40 Bull $10.77
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.2999 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $10.20 $16.88 $26.08 79
Growth DCF $10.22 $15.91 $23.20 78
Owner Earnings $9.60 $15.98 $24.77 75
All 24 models by family
DCF Models
FCF DCF $10.20 $16.88 $26.08 79
Owner Earnings $9.60 $15.98 $24.77 75
5Y Revenue Exit $6.52 $11.37 $17.45 71
5Y EBITDA Exit $10.81 $19.55 $29.83 74
5Y P/E Exit $4.96 $8.39 $11.91 70
10Y Revenue Exit $7.66 $12.26 $18.33 66
10Y EBITDA Exit $10.39 $17.51 $27.13 67
10Y P/E Exit $6.95 $10.35 $14.39 64
Earnings-Based
Graham-Dodd $2.28 $7.89 $10.59 64
Lynch FV $1.82 $2.61 $3.39 61
PEG = 1.0 $1.82 $2.61 $3.39 57
EPV $2.86 $3.71 $4.42 74
Multiples
P/E Multiple $5.54 $7.38 $9.23 63
P/S Multiple $4.28 $5.70 $7.13 58
P/B Multiple $4.28 $5.70 $7.13 55
EV/EBIT $7.66 $11.33 $15.00 65
EV/EBITDA $13.00 $18.45 $23.91 67
EV/Revenue $4.50 $7.87 $11.24 52
Asset-Based
NCAV (Graham) $1.36 $1.82 $2.72 54
Growth DCF
Growth DCF $10.22 $15.91 $23.20 78
Rev-Margin DCF $6.52 $11.49 $17.41 71
Economic Profit
Residual Income $2.39 $2.70 $4.39 69
ROIC Compounder $2.90 $4.22 $5.79 71
Growth Earnings
Growth-Adj P/E $4.73 $6.75 $8.78 67

Open the full fair value analysis →

Notify me when BVS reaches fair value

Put BVS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 56 · Market factors (momentum, volatility) 84

Profitability 54
Margins and returns on capital today
Quality Growth 66
Are margins and returns improving?
Cashflow 78
Earnings quality: real cash, not paper profit
Fin. Strength 21
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 91
Distance to the 52-week high (market factor)
Net Issuance 34
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−9.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 10%

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.0% a year for the price and +3.5% for the forecasts.
Forecast 2026 (sales)+6.6%
Forecast 2027 (sales)+6.6%
Projected 2028 (sales)+6.1%
Projected 2029 (sales)+5.5%
Projected 2030 (sales)+4.9%

BVS screens 84% overvalued. Compare with Abbott Laboratories, →

Compare Bioventus Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −46% · Below median
Profitability
Return on equity (TTM) 16% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 5% · Above median
Operating margin (TTM) 7% · Above median
Growth and dividend
Revenue growth 7% · Above median
Balance sheet
Debt / equity 1.52× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 33.2× · Pricier than median
P/B 5.11× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 1.63× · Cheaper than median
P/FCF 13.2× · Pricier than median
EV/EBITDA 14.4× · Cheaper than median
PEG 1.10× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 4
FUTURE (revenue growth)33 · sector 31
PAST (return on equity)66 · sector 7
HEALTH (low debt)24 · sector 97
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioventus Inc · Fair Value
$7.40 −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bioventus Inc Fair Value". https://www.fairvalue-calculator.com/stock/BVS

Frequently asked questions

Is Bioventus Inc (BVS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $7.40 versus a price of $13.61, about −46% upside (overvalued).
What is the fair value of BVS?
Our model-based fair value for Bioventus Inc is $7.40 (as of Sep 23, 2026), built from audited fundamentals. The current price: $13.61.
What is the quality score of BVS?
Bioventus Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioventus Inc (BVS)?
Our model-based price target is the fair value of $7.40 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $5.54, optimistic scenario $10.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioventus Inc stock forecast for 2026?
Our models put fair value at $7.40, about −46% upside versus a price of $13.61 (overvalued). Cautious scenario $5.54, optimistic scenario $10.77. The calculation is refreshed regularly with new filings.
What is the revenue of Bioventus Inc (BVS)?
Bioventus Inc reported trailing-twelve-month revenue of about $576M (latest available figure, as of Sep 23, 2026).
What growth is priced into Bioventus Inc (BVS)?
For today's price to be fair in a discounted-cash-flow model, Bioventus Inc would have to grow free cash flow by +7.5 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of BVS use?
Our models discount Bioventus Inc at 10.3 %: a base by market capitalisation (small), damped by beta 0.67, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bioventus Inc that is +7.5 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Bioventus Inc (BVS) delivered so far?
Over the past 5 years revenue at Bioventus Inc grew +12.1 % a year. The price currently implies +7.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bioventus Inc (BVS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bioventus Inc (+7.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bioventus Inc (BVS)?
The free-cash-flow yield on the price is 7.61 %: that much free cash flow Bioventus Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bioventus Inc (BVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioventus Inc it is $7.40 per share (as of Sep 23, 2026), against a price of $13.61. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Bioventus Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BVS trades above its calculated fair value: price $13.61, fair value $7.40, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BVS?
No. The price is what the market pays today ($13.61); the fair value is what the company's own numbers justify ($7.40). For Bioventus Inc the two are $6.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioventus Inc worth?
The market values Bioventus Inc at about $938M (market capitalisation, as of Sep 23, 2026). Per share that is $13.61; our models calculate a fair value of $7.40 per share.
What do the bullish and bearish scenarios say about BVS?
Our models span a range for Bioventus Inc: cautious scenario $5.54, base $7.40, optimistic $10.77 per share (as of Sep 23, 2026, price $13.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BVS?
Bioventus Inc trades at a price-to-earnings ratio of 33.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.40 is built from several models across several years. Other multiples: PEG 1.1, P/B 5.1, P/S 1.6, EV/EBITDA 14.4.
What is the PEG ratio of BVS?
The PEG ratio of Bioventus Inc is 1.10 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bioventus Inc (BVS)?
Balance-sheet figures for Bioventus Inc (as of Sep 23, 2026): return on equity 16.5%, debt of 1.52 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is BVS from its 52-week high?
Bioventus Inc trades at $13.61, about 11% below its 52-week high of $15.26 and 109% above the low of $6.51 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $7.40 is for.
Which stocks are comparable to Bioventus Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioventus Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $13.61, calculated fair value $7.40 (−46%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BVS calculated?
We run Bioventus Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $7.40, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bioventus Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioventus Inc (BVS)?
The closing price on Sep 23, 2026 was $13.61. Our model-based fair value is $7.40, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioventus Inc right now?
The price sits above even our optimistic bull case ($10.77). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($5.54 to $10.77) leaves room in how you read the outcome.

Key figures of Bioventus Inc

How large is the market capitalisation of Bioventus Inc (BVS)?
The market capitalisation of Bioventus Inc is $938M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bioventus Inc (BVS)?
The price-to-sales ratio of Bioventus Inc is 1.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bioventus Inc (BVS)?
Earnings per share at Bioventus Inc are $0.4100 (price ÷ EPS = P/E 33.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bioventus Inc (BVS)?
The net margin of Bioventus Inc is 4.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bioventus Inc (BVS)?
The return on equity (ROE) of Bioventus Inc is 16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioventus Inc (BVS)?
On an EBIT basis the return on assets of Bioventus Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioventus Inc (BVS)?
The operating margin of Bioventus Inc is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioventus Inc (BVS)?
Revenue at Bioventus Inc is growing +6.6% versus a year earlier (3y avg +3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Bioventus Inc (BVS) carry?
The net debt of Bioventus Inc is $260M (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bioventus Inc in the live analysis

One click puts Bioventus Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.